| Literature DB >> 16460561 |
Tricia D Miles1, Wayne McLaughlin, Paul D Brown.
Abstract
BACKGROUND: Antimicrobial usage is considered the most important factor promoting the emergence, selection and dissemination of antimicrobial-resistant microorganisms in both veterinary and human medicine. The aim of this study was to investigate the prevalence and genetic basis of tetracycline resistance in faecal Escherichia coli isolates from healthy broiler chickens and compare these data with isolates obtained from hospitalized patients in Jamaica.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16460561 PMCID: PMC1395310 DOI: 10.1186/1746-6148-2-7
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Percentages of E. coli isolates from avian and human sources susceptible (S), intermediate (I) and resistant (R) to antimicrobial agents by NCCLS disc diffusion methods.
| Antimicrobial agent (μg) | Diffusion zone breakpoint (mm) | Avian isolates (n = 34) | Human isolates (n = 48) | ||||
| S | I | R | S | I | R | ||
| Gentamicin (10) | ≤ 12 | 100 | 0 | 0 | 60.4 | 6.3 | 33.3 |
| Kanamycin (30) | ≤ 13 | 2.9 | 5.9 | 91.2 | 8.3 | 18.8 | 43.8 |
| Ampicillin (10) | ≤ 13 | 73.5 | 5.9 | 20.6 | 58.3 | 6.3 | 35.4 |
| Amoxicillin/clavulanate (20) | ≤ 13 | 85.3 | 11.8 | 2.9 | 79.2 | 18.8 | 2.1 |
| Chloramphenicol (30) | ≤ 12 | 88.2 | 8.8 | 2.9 | 68.8 | 6.3 | 25 |
| Ciprofloxacin (5) | ≤ 15 | 64.7 | 26.5 | 8.8 | 89.6 | 0 | 10.4 |
| Enrofloxacin (5) | ≤ 17 | 32.4 | 38.2 | 29.4 | 89.6 | 0 | 10.4 |
| Nalidixic acid (30) | ≤ 13 | 11.8 | 2.9 | 85.3 | 89.6 | 0 | 10.4 |
| Norfloxacin (5) | ≤ 12 | 64.7 | 14.7 | 20.6 | 91.7 | 2.1 | 6.3 |
| Ofloxacin (5) | ≤ 12 | 85.3 | 2.9 | 11.8 | 91.7 | 0 | 8.3 |
| Tetracycline (30) | ≤ 14 | 17.6 | 0 | 82.4 | 39.6 | 16.7 | 43.8 |
Prevalence of multiple resistant patterns in avian and human E. coli isolates
| Number of antimicrobials resistant | Avian isolates (n = 34) | Human isolates (n = 48) | ||
| Antimicrobial resistance pattern (ARP) | ARP frequency | Antimicrobial resistance pattern (ARP) | ARP frequency | |
| 0 | - | 0 | - | 13 |
| 1 | Km; Nal | 1;1 | Km; Tet; Gen | 5;1;1 |
| 2 | Km-Amp; Km-Nal; Km-Tet; Nal-Tet | 3;1;1;1 | Km-Gen; Km-Cm; Km-Tet | 4;1;1 |
| 3 | Km-Nal-Tet | 14 | Km-Gen-Cm; Km-Tet-Amp; Km-Gen-Ofx; Tet-Cm-Amp; Km-Gen-Tet | 2;4;1;1;1 |
| 4 | Km-Nal-Tet-Enr; Km-AMC-Nal-Tet; | 4;1 | Km-Gen-Tet-Amp; Km-Tet-Cm-Amp | 3;3 |
| 5 | Km-Nal-Tet-Nor-Enr; Km-Nal-Tet-Amp-Nor | 1;1 | Km-Tet-Cm-Amp-AMC | 1 |
| 6 | Km-Nal-Tet-Ofx-Nor-Enr | 1 | - | 0 |
| 7 | Km-Nal-Tet-Ofx-Nor-Cip-Enr; Nal-Amp-Tet-Ofx-Nor-Cip-Enr | 1;1 | Km-Gen-Nal-Tet-Enr-Cm-Amp; Km-Gen-Tet-Cip-Enr-Amp-Cm; Km-Tet-Cip-Enr-Nor-Ofx-Amp; Km-Gen-Nal-Tet-Cip-Cm-Amp; Km-Nal-Tet-Ofx-Nor-Cip-Amp | 1;1;1;1;1 |
| 8 | Km-Nal-Amp-Tet-Ofx-Nor-Cip-Enr | 1 | Km-Nal-Tet-Cip-Enr-Nor-Ofx-Cm | 1 |
| ≥9 | Km-Nal-Tet-Amp-Ofx-Nor-Cip-Enr-Cm | 1 | Km-Gen-Amp-Nal-Tet-Cip-Enr-Nor-Ofx | 1 |
Key: Km = kanamycin; Gen = gentamicin; Nal = nalidixic acid; Amp = ampicillin; Tet = tetracycline; AMC = amoxicillin/clavulanate; Cip = ciprofloxacin; Enr = enrofloxacin; Nor = norfloxacin; Ofx = ofloxacin; Cm = chloramphenicol
Figure 1Prevalence of multiple antimicrobial resistance in avian and human E. coli isolates.
Tetracycline susceptibilities of isolates resistant to other antimicrobials
| Agent to which isolate was resistant | Avian isolates (n = 34) | Human isolates (n = 48) | ||
| No. of isolates | Isolates susceptible to tetracycline (%) | No. of isolates | Isolates susceptible to tetracycline (%) | |
| Ampicillin | 7 | 3 (42.9)* | 17 | 0 (0.0) |
| Amoxicillin/clavulanate | 1 | 0 (0.0) | 1 | 0 (0.0) |
| Chloramphenicol | 1 | 0 (0.0)* | 12 | 3 (25.0) |
| Ciprofloxacin | 4 | 0 (0.0) | 5 | 0 (0.0) |
| Enrofloxacin | 10 | 0 (0.0) | 5 | 0 (0.0) |
| Gentamicin | 0 | 0 | 16 | 0 (0.0) |
| Kanamycin | 31 | 5 (16.1)* | 32 | 12 (37.5) |
| Nalidixic acid | 29 | 2 (6.9)* | 5 | 0 (0.0) |
| Norfloxacin | 7 | 0 (0.0) | 3 | 0 (0.0) |
| Ofloxacin | 5 | 0 (0.0)* | 4 | 1 (25.0) |
* p < 0.05 vs. human isolates
Susceptibilities of tetracycline-resistant isolates to other antibiotics
| Antimicrobial agent | Isolates susceptible | |
| Avian isolates (%) (n = 28) | Human isolates (%) (n = 21) | |
| Ampicillin | 24 (85.7)* | 4 (19.0) |
| Amoxicillin/clavulanate | 27 (96.4) | 20 (95.2) |
| Chloramphenicol | 27 (96.4)* | 12 (57.1) |
| Ciprofloxacin | 25 (89.3) | 16 (76.2) |
| Enrofloxacin | 16 (57.6) | 13 (61.9) |
| Gentamicin | 28 (100.0)* | 13 (61.9) |
| Kanamycin | 1 (3.6) | 2 (9.5) |
| Nalidixic acid | 1 (3.6)* | 16 (76.2) |
| Norfloxacin | 21 (75.0) | 18 (85.7) |
| Ofloxacin | 24 (85.7) | 18 (85.7) |
*p < 0.05 vs. human isolates
Figure 2Gel electrophoresis of plasmids isolated from avian and human E. coli isolates. Lanes 1, A7, Lane 2, A17, Lane 3, A28, Lane 4, A30, Lane 5, H57, Lane 6, H60, Lanes 7, H61; Lane 8, H78; Lanes 9 and 10, blank; Lane 11, Plasmid markers, pUC4K (3.9 kb), pTYB11 (7.4 kb) and pHS1 (12 kb).
Figure 3PCR products of tetracycline resistance determinants B and D from tetracycline resistant avian and human E. coli isolates. Lane 1, 1 kb ladder; Lane 2, A13; Lane 3, A16; Lane 4, A19; Lane 5, A20; Lane 6, A20T; Lane 7, H60; Lane 8, H62; Lane 9, H71; Lane 10, H97.